PDCD1 and hepatocellular carcinoma: Additionally, postoperative adjuvant therapy (PAT) with tyrosine kinase inhibitors (TKI) and anti-PD-1 antibodies can improve surgical outcomes for HCC patients at high risk of recurrence.